Cargando…

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study

INTRODUCTION: Little evidence appears to exist for the use of anakinra, a recombinant interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone or combined with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammatory state. PATIENTS A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aomar-Millán, Ismael Francisco, Salvatierra, Juan, Torres-Parejo, Úrsula, Faro-Miguez, Naya, Callejas-Rubio, José Luis, Ceballos-Torres, Ángel, Cruces-Moreno, María Teresa, Gómez-Jiménez, Francisco Javier, Hernández-Quero, José, Anguita-Santos, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Im - Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782569/ https://www.ncbi.nlm.nih.gov/pubmed/33400157 http://dx.doi.org/10.1007/s11739-020-02600-z

Ejemplares similares

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Dexametasona frente a metilprednisolona ajustada al peso en pacientes con neumonía moderada-grave por SARS-CoV-2
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients
por: Bahl, Amit, et al.
Publicado: (2021)

Tratamiento y evolución del síndrome de tormenta de citoquinas asociados a infección por SARS-CoV-2 en pacientes octogenarios
por: Callejas Rubio, José Luis, et al.
Publicado: (2020)

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
por: Bozzi, Giorgio, et al.
Publicado: (2021)

Bacterial infections in patients hospitalized with COVID-19
por: Moreno-Torres, Víctor, et al.
Publicado: (2021)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Anakinra/tocilizumab: Primary biliary cholangitis: case report
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial
por: Violi, Francesco, et al.
Publicado: (2019)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Relationship between the severity of persistent symptoms, physical fitness, and cardiopulmonary function in post-COVID-19 condition. A population-based analysis
por: Jimeno-Almazán, Amaya, et al.
Publicado: (2022)

Thoracic aortic aneurysm and atrial fibrillation: clinical associations with the risk of stroke from a global federated health network analysis
por: Proietti, Riccardo, et al.
Publicado: (2023)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series
por: Beltrão, Beatriz Amorim, et al.
Publicado: (2021)

The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
por: Rubio-Rivas, Manuel, et al.
Publicado: (2021)

Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
por: Formiga, Francesc, et al.
Publicado: (2021)

Early effects of Anakinra in corticosteroid naïve SOJIA patients
por: Wulffraat, NM, et al.
Publicado: (2008)

Mortality predictors in patients with COVID-19 pneumonia: a machine learning approach using eXtreme Gradient Boosting model
por: Casillas, N., et al.
Publicado: (2022)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023)

Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry
por: Rubio-Rivas, Manuel, et al.
Publicado: (2022)

Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids
por: Calò Carducci, Francesca I., et al.
Publicado: (2020)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
por: Potere, Nicola, et al.
Publicado: (2020)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry
por: Núñez-Gil, Iván J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1mcs0bb5h0k1q8e2oraodmid83